The main results of this study were (i) the differences between PC and CCL18 levels in the ability to predict neurodegeneration in MS patients and (ii) the positive correlation between PC and CCL18 levels present in diseased and healthy conditions. Here, CCL18 is linked to myeloid sarcoma.